← Back to feed

Faron Pharmaceuticals Oy

FARN · AIM · Health Care · mcap £77m today

All announcements

All RNS · 82 Key events · 52

06 Oct 26

Composition of Faron Pharmaceutical’s Shareholders’ Nomination Board

(AIM: FARN, First North: FARON), a global, clinical-stage biopharmaceutical company focused on creating innovative cancer treatments that leverage the patient’s own immune system, today announces that the following members have been re-elected by a meeting...
RNS 9807643 ↗
30 Sep 26

Convertible bond amortization payment deferred by mutual agreement with HCM

(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that the Company and Heights Capital Management, Inc.
RNS 9797887 ↗
17 Sep 26

Issuance of warrants

(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company, announces that it has issued to IPF Fund II SCA, SICAV-FIAR (“IPF”) 153,917 additional warrants over ordinary shares in the Company (“Warrants”), following the the amortisation of...
RNS 9776550 ↗
17 Sep 26

Holding(s) In Company
RNS 9776205 ↗
07 Sep 26

Holding(s) In Company
RNS 9759617 ↗
04 Sep 26

Holding(s) In Company
RNS 9756531 ↗
26 Aug 26

Half-year Results

Strengthened balance sheet supports advancement into randomized Phase 2b trial in higher-risk MDS
RNS 9740173 ↗
19 Aug 26

Notice of Half-Year Financial Results

Faron Pharmaceuticals will publish its half-year financial results for January-June 2026 on Wednesday 26 August 2026
RNS 9728795 ↗
05 Aug 26

Holding(s) In Company
RNS 9706616 ↗
04 Aug 26

Holding(s) In Company
RNS 9704321 ↗
03 Aug 26

Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds

(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that the Company has approved the exercise of 3,657,321 special rights entitling to 3,657,321 shares in the Company, for an aggregate...
RNS 9701683 ↗
27 Jul 26

Inside Information: Faron announces encouraging first overall survival data from frontline higher-risk (HR) MDS patients in the BEXMAB phase 1/2 trial

Inside Information: After a median follow-up of 14.9 months, median overall survival has not yet been reached in frontline HR MDS without TP53 mutations, nor has it yet been reached for monoallelic TP53 mutated patients.
RNS 9687517 ↗
24 Jul 26

Holding(s) In Company
RNS 9685191 ↗
01 Jul 26

Grant of Options
RNS 9647336 ↗
22 Jun 26

Holding(s) In Company
RNS 9630257 ↗
17 Jun 26

Holding(s) In Company
RNS 9623779 ↗
17 Jun 26

Holding(s) In Company
RNS 9621787 ↗
15 Jun 26

Holding(s) In Company
RNS 9619149 ↗
11 Jun 26

Holding(s) In Company
RNS 9614298 ↗
11 Jun 26

Registration of Treasury Shares

Capitalised terms used in this announcement have the meanings given to them in the announcement made on 28 May 2026 at 15:35 EEST regarding the issue of treasury shares to the Company, unless the context provides otherwise.
RNS 9614289 ↗
10 Jun 26

Holding(s) In Company
RNS 9612211 ↗
08 Jun 26

Holding(s) In Company
RNS 9607550 ↗
05 Jun 26

Faron Pharmaceuticals Receives Decision from Nasdaq Helsinki Disciplinary Committee

The Disciplinary Committee dismissed two of the alleged breaches claimed by the market surveillance, importantly, an allegation that the Company’s administration was not organized in a manner required of a listed company.
RNS 9604656 ↗
04 Jun 26

Holding(s) In Company
RNS 9602332 ↗
03 Jun 26

Registration of New Shares

Capitalised terms used in this announcement have the meanings given to them in the announcement made on 3 June 2026 at 09:00 EEST regarding the amortisation payment and approval of share subscriptions based on special rights, unless the context provides otherwise.
RNS 9600059 ↗
03 Jun 26

Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds

(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that the Company has approved the exercise of 3,366,377 special rights entitling to 3,366,377 new Shares, for an aggregate subscription...
RNS 9598329 ↗
01 Jun 26

Holding(s) In Company
RNS 9595321 ↗
28 May 26

Holding(s) In Company
RNS 9590453 ↗
28 May 26

Issue of Treasury Shares to the Company

(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces that the Board of Directors of Faron (the “Board”) has resolved to issue 21,469,427 treasury shares to the Company...
RNS 9590421 ↗
28 May 26

Special Rights attached to the First and Second Tranche of Bonds

(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces that the Board has resolved, based on the authorisation granted by the General Meeting held on 4 May 2026, to issue...
RNS 9590414 ↗
18 May 26

Holding(s) In Company
RNS 9571796 ↗
06 May 26

Termination of Liquidity Provision Service

Faron has terminated the liquidity providing agreement with Lago Kapital
RNS 9553558 ↗
05 May 26

Holding(s) In Company
RNS 9552158 ↗
05 May 26

Directorate Appointment

(“Faron”) (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies, is pleased to announce the appointment of Dr.
RNS 9550492 ↗
04 May 26

Result of AGM

Faron Pharmaceuticals Ltd: Results of the Annual General Meeting
RNS 9550358 ↗
30 Apr 26

Issuance of warrants

(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company, announces that it has issued to IPF Fund II SCA, SICAV-FIAR (“IPF”) 321,523 additional warrants over ordinary shares in the Company (“Warrants”), following the the amortisation of...
RNS 9545170 ↗
22 Apr 26

Holding(s) In Company
RNS 9533117 ↗
20 Apr 26

Holding(s) In Company Holder at 25–30 %

TR-1: Standard form for notification of major holdings
RNS 9527938 ↗
20 Apr 26

Holding(s) In Company Holder at 25–30 %

TR-1: Standard form for notification of major holdings
RNS 9527793 ↗
16 Apr 26

Holding(s) In Company
RNS 9524535 ↗
14 Apr 26

Remaining offer shares registered with Finnish Trade Register

Faron Pharmaceuticals Ltd: Remaining offer shares registered with Finnish Trade Register
RNS 9519758 ↗
14 Apr 26

Registration of New Shares

Capitalised terms used in this announcement have the meanings given to them in the announcement made on 13 April 2026 at 14:00.
RNS 9518913 ↗
13 Apr 26

Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds

(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that the Company has approved the exercise of 3,572,851 special rights entitling to 3,572,851 new Shares, for an aggregate subscription...
RNS 9517288 ↗
10 Apr 26

Notice Of Faron Pharmaceuticals Ltd’s Annual General Meeting

Shareholders of Faron Pharmaceuticals Ltd (the “Company”) are notified of the Annual General Meeting (the “AGM”) to be held on 4 May 2026 at 10:00 a.m.
RNS 9515301 ↗
10 Apr 26

New shares registered with Finnish Trade Register

Faron Pharmaceuticals Ltd: New shares registered with Finnish Trade Register
RNS 9515253 ↗
09 Apr 26

Faron publishes final results of its EUR 40.1 million rights issue

Faron publishes final results of its EUR 40.1 million rights issue
RNS 9513476 ↗
08 Apr 26

Inside Information: Faron publishes preliminary results of its successful rights issue

Inside Information: Faron publishes preliminary results of its successful rights issue
RNS 9510983 ↗
31 Mar 26

Director/PDMR Shareholding Director buysRepeated director buys

(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Tuomo Pätsi, Non-Executive Chairman of the Company, subscribed 400,002 ordinary shares in Faron at price of €0.5...
RNS 9499031 ↗
30 Mar 26

Suspension - Faron Pharmaceuticals Oy

RNS 9497618 ↗
26 Mar 26

Faron appoints new CTO to strengthen late-stage development activities

(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company, announces the appointment of Mr.
RNS 9492461 ↗
25 Mar 26

Director/PDMR Shareholding
RNS 9491102 ↗
24 Mar 26

Holding(s) In Company
RNS 9490011 ↗
19 Mar 26

Director/PDMR Shareholding Director buys

(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Juho Jalkanen, CEO of the Company, subscribed 23,656 ordinary shares in Faron at price of EUR 0.5 per share on 17...
RNS 9482089 ↗
19 Mar 26

Director/PDMR Shareholding Director buys

(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Yrjö Wichmann, other senior manager of the Company, acquired 10,000 ordinary shares in Faron at price of EUR...
RNS 9481600 ↗
19 Mar 26

Director/PDMR Shareholding
RNS 9481203 ↗
12 Mar 26

Holding(s) In Company
RNS 9472099 ↗
11 Mar 26

The Finnish Financial Supervisory Authority has approved Faron's rights offering prospectus

(AIM: FARN, First North: FARON, “Faron” or the “Company”) announced through a company announcement on 10 March 2026 a resolution by the Company’s Board of Directors on a fully committed rights offering of approximately EUR 40 million (the “Offering”) as...
RNS 9470076 ↗
11 Mar 26

Holding(s) In Company
RNS 9468969 ↗
10 Mar 26

Inside Information: Faron publishes the terms and conditions of a fully covered rights offering of approximately EUR 40 million and updates cash runway

Inside Information: Faron publishes terms and conditions for approximately EUR 40m rights offering fully-covered from combination of cornerstone investments, subscription commitments, and guarantees and updates cash runway
RNS 9466613 ↗
09 Mar 26

Update to Faron’s Financial Calendar and date of the Annual General Meeting in 2026

(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces an update for the Company’s financial calendar 2026.
RNS 9465609 ↗
04 Mar 26

Faron Pharmaceuticals Ltd’s Annual Report 2025 published

(AIM: FARN, First North: FARON), announces a correction to the company announcement of its Annual Report 2025, originally published on 4 March 2026 at 09:15 EET.
RNS 9458870 ↗
04 Mar 26

Faron Pharmaceuticals Ltd’s Annual Report 2025 published

(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today published the Annual Report for 2025.
RNS 9457720 ↗
04 Mar 26

Faron’s Financial Statements Release 1 January to 31 December 2025

Continued steady progress with bexmarilimab and solidifying position as a leading macrophage based immunotherapy under development
RNS 9456873 ↗
02 Mar 26

Result of General Meeting

TURKU - FINLAND 2 March 2026 – Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces that the extraordinary general meeting (the "EGM") of the...
RNS 9453379 ↗
09 Feb 26

Notice To The Extraordinary General Meeting

Shareholders of Faron Pharmaceuticals Ltd (business ID: 2068285-4, the “Company”) are notified of the Extraordinary General Meeting (the “EGM”) to be held on 2 March 2026 at 10:00 a.m.
RNS 9422265 ↗
09 Feb 26

Inside Information: Faron Pharmaceuticals Ltd is planning a rights offering of approximately EUR 40 million to strengthen its capital structure and to drive lead asset bexmarilimab to key milestones

Inside Information: Faron Pharmaceuticals Ltd is planning a rights offering of approximately EUR 40 million to strengthen its capital structure and to drive lead asset bexmarilimab to key milestones
RNS 9422254 ↗
03 Feb 26

Registration of New Shares

Capitalised terms used in this announcement have the meanings given to them in the announcement made at 9.00 a.m.
RNS 9405883 ↗
03 Feb 26

Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds

(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that the Company has approved the exercise of 909,517 special rights entitling to 909,517 new Shares, for an aggregate subscription...
RNS 9403305 ↗
13 Jan 26

Director/PDMR Shareholding
RNS 9351087 ↗
08 Jan 26

Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds

(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that the Company has approved the exercise of 453,979 special rights entitling to 453,979 existing treasury shares, for an aggregate...
RNS 9342455 ↗
17 Dec 25

Composition of Faron Pharmaceutical’s Shareholders’ Nomination Board

(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that the following members have been re-elected by a meeting of the Company's five largest shareholders to...
RNS 9303825 ↗
11 Dec 25

Faron issues second tranche of bonds with an aggregated principal amount of EUR 10 million under its convertible bond arrangement

(AIM: FARN, First North: FARON, “Faron” or the “Company”), a clinical-stage biopharmaceutical company developing novel immunotherapies, announced on 3 April 2025 that the Company has entered into a subscription agreement (the “Subscription Agreement”) with...
RNS 9290172 ↗
04 Dec 25

Holding(s) in Company
RNS 9276829 ↗
03 Dec 25

Registration of New Shares

Capitalised terms used in this announcement have the meanings given to them in the announcement made at 9.00 a.m.
RNS 9273038 ↗
03 Dec 25

Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First Tranche Bonds

(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that the Company has approved the exercise of 517,795 special rights entitling to 517,795 new Shares, for an aggregate subscription...
RNS 9271711 ↗
02 Dec 25

Grant of Options
RNS 9268915 ↗
01 Dec 25

Appointment of CFO New CFO

Faron appoints new CFO to support next phase of growth
RNS 9265813 ↗
27 Nov 25

Faron’s Financial Calendar for 2026

(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces the following dates for the Company’s financial reporting in 2026:
RNS 9259868 ↗
24 Nov 25

INSIDE INFORMATION: FARON INTENDS TO ISSUE SECOND TRANCHE OF BONDS WITH AN AGGREGATED PRINCIPAL AMOUNT OF EUR 10 MILLION UNDER ITS CONVERTIBLE BOND ARRANGEMENT

Inside Information: Faron intends to issue second tranche of bonds with an aggregated principal amount of EUR 10 million under its convertible bond arrangement
RNS 9254070 ↗
28 Oct 25

Approval of Share Subscriptions Based on Special Rights in connection with Advanced Amortisation of the First Tranche Bonds

(AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that the Company has approved the exercise of 451,803 special rights entitling to 451,803 new Shares, for an aggregate subscription...
RNS 9197620 ↗
21 Oct 25

Holding(s) In Company
RNS 9184980 ↗
20 Oct 25

Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinical profile of bexmarilimab in treatment-naïve HR-MDS patients

Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinical profile of bexmarilimab in treatment-naïve HR-MDS patients with an 85% ORR and a 45% CR rate, bolstered by pharmacodynamic insights
RNS 9180236 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.